Novo Nordisk | NVO - 销售收入

金融业

DKK

DKK 76.18B

现金及等价物

DKK 38.94B

DKK 1.95B

DKK 25.71B

DKK 32.79B

DKK 118.72B

股息收益率

DKK 3.11

DKK 5.18B

DKK 31.44B

DKK 54.39K

EPS每股收益

DKK 1.02

股本和储备

DKK 26.56B

DKK 64.01B

债务利息支出

DKK 82.1M

DKK 3.43B

DKK 14.02B

DKK 157.42B

DKK 4.03B

DKK 6.5B

DKK 5.18B

普通股股本

DKK 4.44B

13.93

DKK 25.52B

DKK 12.53B

销售和管理费用

DKK 2.86B

DKK 42.85B

贸易债权人

DKK 4.46B

应收帐款人

DKK 14.27B

	销售	更改		日
ANI Pharmaceuticals	USD 237.5M		9.56M	2026-03
Aurora Cannabis	CAD 94.19M		3.82M	2025-12
Bausch Health Companies	USD 2.5B		300M	2026-03
Bristol-Myers Squibb	USD 11.49B		1.01B	2026-03
Canopy Growth	CAD 74.54M		7.86M	2025-12
Corcept Therapeutics	USD 164.9M		37.22M	2026-03
Drreddys Laboratories	INR 87.27B		1.82B	2025-12
Eli Lilly	USD 19.8B		500M	2026-03
GlaxoSmithKline	GBP 7.63B		991M	2026-03
Merck	USD 16.29B		110M	2026-03
Nektar Therapeutics	USD 21.81M		2.32M	2025-12
Novartis	USD 13.11B		226M	2026-03
Novo Nordisk	DKK 96.82B		17.68B	2026-03
Novo Nordisk	DKK 12.53B		2.44B	2025-12
Pacira	USD 177M		19.87M	2026-03
Perrigo	USD 969M		141M	2026-03
Phibro Animal Health	USD 373.91M		10.02M	2025-12
Prestige Brands	USD 283.44M		9.34M	2025-12
Sanofi	EUR 11.24B		60M	2026-03
Supernus Pharmaceuticals	USD 207.71M		3.89M	2026-03
Zoetis	USD 2.3B		100M	2026-03